All 1 tracked stories fall under one category: regulation. Australasian Menopause Society is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 2 original sources on average, compared with 3.2 for the broader beat in this window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Claire
All 1 tracked stories fall under one category: regulation. Australasian Menopause Society is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 2 original sources on average, compared with 3.2 for the broader beat in this window. The 5 average consequence score is below the beat benchmark of 5.7 in the same window. We currently track 1 Healthcare story that mention Claire, all published on February 27, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 29 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Claire. Shared-story counts are live from our verified record — not editorial picks.
Australian women are facing significant financial barriers to accessing testosterone therapy, often paying substantially more than men for the same hormone treatment. While the therapy is clinically recognized for treating sexual dysfunction in postmenopausal women, the lack of subsidized options highlights a systemic gap in the national pharmaceutical framework.